A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild to moderate COPD
- Smokers or ex-smokers
- post-menopausal females
Exclusion Criteria:
- Past history or current evidence of clinically significant heart disease
- Lung disease other than COPD
- Treatment with systemic steroids within 8 weeks of study visit 2
- Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Active Treatment
|
30mg oral tablets twice daily (bid) for 14 days
|
|
Placebo Comparator: 2
Placebo Treatment
|
Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alanine Aminotransferase (ALT)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
ALT level greater than 3 times the upper limit of normal
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Aspartate Aminotransferase (AST)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
AST level greater than 3 times the upper limit of normal
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Creatine Kinase (CK)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Total Bilirubin
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Creatinine
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Creatinine level greater than the upper limit of normal
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Haemoglobin (Hb)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Reticulocytes
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Leucocytes
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
QTcF (QT Interval Corrected for Heart Rate by Fridericia's Method)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
QTcF interval greater than 450 ms
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
QTcF
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
QTcF change from baseline greater than 60 ms
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
FEV1 (Forced Expiratory Volume in the First Second)
Time Frame: Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
Change from baseline to Day 14
|
Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose)
|
|
Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC(0-12))
Time Frame: Pre-dose on day -1 to day 15 (end of dosing)
|
AUC(0-12) following 14 days' dosing
|
Pre-dose on day -1 to day 15 (end of dosing)
|
|
Observed Peak or Maximum Plasma Concentration Following Drug Administration (Cmax)
Time Frame: Pre-dose on day -1 to day 15 (end of dosing)
|
Cmax following 14 days' dosing
|
Pre-dose on day -1 to day 15 (end of dosing)
|
|
Time to Reach Observed Peak or Maximum Concentration Following Oral Drug Administration (Tmax)
Time Frame: Pre-dose on day -1 to day 15 (end of dosing)
|
tmax following 14 days' dosing
|
Pre-dose on day -1 to day 15 (end of dosing)
|
|
Terminal Half-life of Drug in Plasma (t1/2)
Time Frame: Pre-dose on day -1 to day 15 (end of dosing)
|
t1/2 following 14 days' dosing
|
Pre-dose on day -1 to day 15 (end of dosing)
|
|
Renal Clearance of Drug From Plasma (CLR)
Time Frame: Pre-dose on day -1 to day 15 (end of dosing)
|
CLR following 14 days' dosing
|
Pre-dose on day -1 to day 15 (end of dosing)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sputum Absolute Neutrophil Count
Time Frame: Pre-dose day -1 to post-dose on day 14
|
Change from baseline to Day 14 in absolute neutrophil count
|
Pre-dose day -1 to post-dose on day 14
|
|
Sputum Differential Neutrophil Count
Time Frame: Pre-dose day -1 to post-dose on day 14
|
Change from baseline to Day 14 in percentage neutrophil count
|
Pre-dose day -1 to post-dose on day 14
|
|
AZD9668 Sputum Concentrations
Time Frame: Pre-dose day -1 to post-dose on day 14
|
Pre-dose day -1 to post-dose on day 14
|
|
|
Quantitative Sputum Bacteriology
Time Frame: Pre-dose day -1 to post-dose on day 15
|
Number of patients with an increase in bacteriological count from Day -1 to Day 15
|
Pre-dose day -1 to post-dose on day 15
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kristina Panke, Parexel International GmbhH (CRO)
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D0520C00002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.